Mississippi boards bar licensees from research-grade and non-FDA-approved peptides

Mississippi's medical licensure, nursing and pharmacy boards issued a joint statement prohibiting licensees from compounding, administering, dispensing, recommending or prescribing non-FDA-approved or research-grade peptides, and from delegating those acts to other people ^[1]. The prohibition targets products that have not been through FDA approval, not FDA-approved medicines.

The statement is a joint action by three boards covering physicians, nurses and pharmacists. Most state positions on compounded peptides and GLP-1 drugs have come from pharmacy boards alone; Alabama reached physician-office compounding through a separate ruling from its medical board rather than the pharmacy board ^[2]. When the Mississippi statement takes effect, how it will be enforced and what penalties it carries have not been reported ^[1].

The federal floor underneath

States generally do not set their own substantive standard for what may lawfully be compounded. That eligibility baseline is set federally, mainly by Sections 503A and 503B of the Food, Drug, and Cosmetic Act, and it is largely uniform across the country. A state board can add stricter requirements, but it cannot relax federal ones ^[2].

Peptides sit in an unsettled zone. In 2023 the FDA placed a group of popular peptides in Category 2 of the interim 503A bulk substances scheme, effectively barring their compounding on safety grounds. In April 2026 the agency removed twelve of those peptides from Category 2 and scheduled Pharmacy Compounding Advisory Committee meetings to consider several of them for the 503A Bulks List ^[2]. Removal from Category 2 is not an authorization to compound; those peptides were not moved to Category 1, leaving them neither flagged as a significant safety risk nor affirmatively cleared ^[2].

GLP-1 drugs have moved the other way. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) were never on the 503A or 503B Bulks Lists. Their compounding was allowed only through the drug shortage pathway, and that pathway closed as the FDA resolved the shortages ^[2]. The agency has since issued compliance policy guidance on what makes a compounded product essentially a copy of an approved drug, proposed excluding the molecules from the 503B Bulks List, and sent successive waves of warning letters to compounders and telehealth marketers ^[2].

Enforcement differs sharply by state

Ohio's July 2025 guidance treats semaglutide and tirzepatide as no longer compoundable as copies, expressly prohibits the investigational peptides retatrutide and cagrilintide, and requires active ingredients from an Ohio-licensed distributor. Ohio's pharmacy board reports summarily suspending more than thirty clinics and medical spas since the start of 2025 ^[2]. Washington imposed a stop-service order on a GLP-1 sterile compounder ^[2]. California's rewritten compounding rules, effective October 1, 2025, require pharmacists to verify and document a clinically significant, patient-specific difference ^[2]. Connecticut has pursued distributors, med spas and clinics under its unfair trade practices law rather than through pharmacy licensing ^[2].

Compliance guidance for companies in this market says active ingredients should be pharmaceutical grade, never labeled research use only, sourced from an FDA-registered establishment, and accompanied by a valid certificate of analysis ^[2]. That research-use-only labeling is what the Mississippi boards singled out.

Why it matters for patients

Patients in Mississippi who receive peptides through a physician, nurse practitioner, pharmacy or clinic licensed by one of the three boards may find that channel closes. How existing prescriptions, standing orders or supplies already in patients' hands would be handled has not been reported ^[1].

The statement applies to non-FDA-approved and research-grade peptides. FDA-approved medicines are approved products and are not what the boards described; whether a clinician can keep prescribing an FDA-approved GLP-1 is governed by other rules. Products sold as research grade or research use only are not the same as prescription drugs dispensed by a licensed pharmacy, and state boards have treated sourcing and labeling as central compliance questions ^[2]. Because enforcement intensity varies widely, a compounded product or telehealth service available in one state may not be available in another ^[2].

What happens next

The FDA has scheduled Pharmacy Compounding Advisory Committee meetings to consider several removed peptides for the 503A Bulks List, and has proposed excluding the GLP-1 molecules from the 503B Bulks List ^[2]. Separately, Lilly and Novo Nordisk have filed trademark, patent and false advertising suits across dozens of jurisdictions, and at least one compounder has countersued on antitrust grounds ^[2]. Mississippi's effective date, enforcement mechanism and any penalty provisions have not been reported ^[1].